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A  specific  polysaccharide  responsible  for  the  type  specificity of  Type  I 
meningococci has been prepared by Scherp and Rake (1) and it has been shown 
that the antipolysaccharide in Type I antimeningococcal horse sera is effective 
in protecting mice inoculated with virulent Type I  meningococci (2).  Rake 
and Scherp stated that ill several Type I  horse anfisera, 90 to 99 per cent of 
the protective antibodies in the sera  could be removed by absorption with 
Type I polysaccharide (2).  In the course of an investigation of the antigenic 
properties of materials obtained from Type I  meningococci, it was noted that 
several Type I specific anfimeningococcal rabbit and chicken sera (3) contained 
only very small amounts of antipolysaccharide and that after absorption of the 
antipolysaccharide  these  sera  still  contained considerable  amounts  of type- 
specific antibody.  To study this problem, measurements were made by the 
quantitative agglutinin  (4)  and precipitin methods  (5-7)  of the amounts of 
type-specific and group-specific (species-specific) antibodies and of the type- 
specific  antipolysaccharide present  in  antimeningococcal horse,  rabbit,  and 
chicken antisera as well as in sera from a number of individuals convalescing 
from Type I  meningitis.  By determining  the protective power of the sera 
for mice  (8,  9)  before and  after removal of the  different antibodies  it was 
possible  to  determine  with  which  kinds  of  antibody protective power  was 
associated. 
EXPERIMENTAL 
PreparaHon of  Bacter{cal  Suspensions.--Freshly  isolated  lyophiUzed  strains  of  meningococd 
Type I or II,  obtained  from Dr. H. E. Alexander and Dr. J. J. Phalr,  were inoculated  into 
peptone blood  broth and  transferred  until  good  growth  was obtained  to  Difco  tryptose  phos- 
phate broth or to the casein  hydrolysate  medium described  by Mueller and Hinton (i0) 
prepared  without agar.  100 ml. flasks  of  broth  were inoculated  and after  20  hours'  incuba- 
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tion the contents of each 100 ml. flask was used for inoculating a  flask containing 1 liter of 
broth.  After 24 hours' incubation, the cultures were killed by addition of formalin to a con- 
centration of 1 per cent.  The organisms were centrifuged in Sharples centrifuge, and  sus- 
pended in saline.  The bacterial suspension was then heated to 58°C. for 45 minutes, and 
washed seven times with saline.  The washed meningococci were suspended in saline con- 
taining 0.01 per cent merthiolate and centrifuged lightly to remove debris. 
Type I  Meningococcus Polysaccharide.--A  sample of Type  I  polysaccharide No.  18  (1) 
was kindly supplied by Dr. H. W. Scherp.  This sample was reported by Scherp (11) to con- 
tain at least 20 per cent of a second group-specific substance which reacted with antimeningococ- 
cal serum.  Preparations M6C and M9B2 were prepared from autolyzed 2 week old cultures 
of Type I meningococci grown on Difco tryptose phosphate or on casein hydrolysate medium 
without the use of barium acetate and sodium carbonate or of glacial acetic acid.  The broth 
was concentrated by ultrafiltration and the polysaccharide obtained by repeated precipita- 
tion with 4 volumes of alcohol, and removal of protein by saturation with ammonium sulfate. 
The solution was then dialyzed and the polysaccharide precipitated with safranin; the safranin 
was removed by repeated solution in 20 per cent sodium acetate and precipitation of the 
polysaccharide with alcohol.  In the case of M9B~, fractional precipitation with methyl and 
ethyl alcohol was used instead of safranin.  These preparations appeared to contain only 
traces of  group specific substances.  Their  properties  have  been  described in detail (16). 
Antisera.--Type  I  horse antimeningococcal serum H1095 was  obtained from  Dr.  Jules 
Freund of the New York City Department of Health Laboratories.  The pool (Rx) of Type 
I  antimeningococcal rabbit sera was provided by Dr. H. E. Alexander and the other Type I 
rabbit serum (R.L) was obtained from Lederle Laboratories.  Types I and II antimeningococcal 
chicken sera were prepared by immunizing chickens with live cultures of Types I  and II 
meningococci as described by Phair, Smith, and Root (3).  Sera from convalescent menin- 
gitis cases were obtained from Presbyterian, Babies, Willard Parker, and Mount Sinai Hos- 
pitals and from the U. S. Marine Hospital, Staten Island, through the courtesy of Drs. R. F. 
Loeb,  H.  E.  Alexander, R.  Ottenberg,  G.  Schwartzman, and L.  Sofian.  All patients had 
received sulfonamide treatment and the sera were obtained after about 1 week of convalescence 
or shortly before discharge from the hospital. 
Quantitative Determination of Antibody N.--The total agglutinin N  and the group-specific 
agglutinin N  present in the antisera were measured by the quantitative agglutinin method 
described in (4)  using suspensions of Type I  and Type II meningococci respectively.  The 
Type I antipolysaccharide in the horse and rabbit sera was determined at 0°C. by the quantita- 
tive precipitin method (5) and the antipolysaccharide content of the chicken and human sera 
was estimated by the micro method devised by Heidelberger and MacPherson (6) and described 
in greater detail in (7).  The modified Folin-Ciocalteau tyrosine reagent was used and calibra- 
tion curves were  obtained with electrophoreticaily separated  chicken and human gamma 
globulin solutions respectively.  Before  measuring the  agglutinin or  precipitin content  of 
the  human or chicken sera, the complement was first removed on the precipitate formed by 
addition of 0.045 mg. egg albumin N  and 0.40 rag. antiegg albumin N  per 4.5 ml. serum as 
recommended by Heidelberger and Mayer (12).  A summary of quantitative immunochemical 
methods is given in (13). 
Mouse Protection Tests.--With the stronger sera, the standard U. S. Public Health Service 
procedure described by Branham (14)  was used in which var.ying doses of serum are given 
followed by an injection of I00,000 ~.L.D.  of meningococci in mucin suspension.  The pro- 
tection tests were carried out with a different strain of Type I meningococci than was used for 
the quantitative agglutinin determinations.  With weaker sera or when only small quantities 
of serum were available, a constant dose of serum was injected per mouse followed by varying 
doses of meningococci.  The protective power of each serum after absorption with Type  I E.  A.  KABAT~  C.  P.  M'ILLER~  H.  KAISER~  AND  A.  Z.  FOSTER  3 
and Type II suspensions and with various polysaccharide preparations was compared with a 
similarly diluted control of unabsorbed serum and saline.  The results in Tables II and III 
are expressed as the percentage of the original  protection potency remaining in the supernatant. 
RESULTS 
Table I summarizes the data on the potency of the various sera in protecting 
mice against Type  I  meningococci.  It may be noted  that  the  most potent 
sera were the horse and rabbit therapeutic Type I  sera (H1095  and I~L) and 
that the chicken and human sera were much less effective.  A  comparison of 
the protective power of the sera with the total agglufinin N  content, determined 
TABLE  I 
Protective _Potency of ltorse (It), Rabbit (R), Chicken (C) Type I  A ntimeningococcus Sera, 
and of Sera from Human Convalescents (M) 
Serum No.  Type 
EI1095 ........ 
Et antitoxin  .... 
Rx (pool) ..... 
~L ............ 
2851 ........... 
ME8.2 ......... 
~I10.1 ......... 
~10.2 ........ 
~14.2 ......... 
~18.2 ........ 
Antibody N 
removed per ml. 
serum.by Type I 
menlngococcl 
mg. 
1.15 
0.56 
0.24 
0.50 
0.55 
0.12 
0.06 
0.10 
0.05 
Serum dilution protecting against Type I 
meningococci* 
100,000 M.L.D. 
11400 -1/8oo 
1/4000-1/8000 
1/15 
1/60-1/70 
1/15-1/30 
1/20 
1/20 
10,005 ~.LD. 
11350 
1000 M.L.D. 
1/30 
1/10-1/20 
Additional sera tested: M9 failed to protect against 10 ~.LD. in 1/20 dilution; M18.1 
failed to protect against 1000 ~.L.D. in 1/4 dilution. 
* 0.5 ml, serum dilution used per mouse. 
with a  Type I  meningococcus suspension, indicates no correlation of antibody 
nitrogen content  and protective power even among  sera of the same animal 
species. 
In Table II, measurements of the Type I  and Type II agglutinin N  and the 
Type I  antipolysaccharide content of the horse, rabbit, and chicken sera are 
given,  together  with  values for  the  fraction of mouse  protective activity re- 
maining in the supernatant after removal of these different antibody fractions. 
It may be noted that with sera H1095,  RL  and  C841,  842, and 851,  the  total 
Type  I  agglutinin N  content  was  considerably greater  than  the  sum  of  the 
Type  II  agglutirdn N  and  the  antipolysaccharide N  removed  with  purified 
preparations M6C  or M9B2, indicating the presence of other Type I  specific 
antibody in these sera besides the antipolysaccharide.  In all these sera except Ct~EMICAL STUDIES ON  BACTERIAL AGGLUTINATION.  VII 
H1095, the antipolysaccharide content as measured with polysaccharide prep- 
aration 18 (Scherp) was only very slightly higher than that obtained with the 
other samples. 
In all  of the rabbit  and  chicken Type I  sera,  removal of the antipolysac- 
charide with any of the three samples of polysaccharide or of the Type II ag- 
glutinin left most of the protective antibody in the supernatant, but absorption 
with  the homologous Type I  suspension effected complete or almost complete 
TABLE II 
A ntibody Nitrogen and Mouse-Protectlve Power Removed from A ntimeningococous Horse (H), 
Rabbit (R), and Chicken (C) Sera by Types I and H  Meningococci and by Purified Type I 
Meningococcus Polysaccharide 
Serum 
H1095 ........ 
H antitoxin .... 
P.x (pool) ..... 
RL ........... 
C84a .......... 
C84~  .......... 
C851 .......... 
C135 .......... 
Antiserum -  Antibody  Nserumremoved=  by  per ml. of 
to mening-  j  Meningococcus 
I.  coll  
Type I  Type I 
mg./ml,  r~g/.ml, 
I  1.15  0.70 
?  0.56  0.58 
I  0.24  0.11 
I  0.50  0.01 
I  0.49  0.25 
I  0.25  0.16 
I  0.55  0.28 
II  0.20  0.32 
Type I  poly- 
saccharide 
Percentage of protective power 
against Type I meningococci  in 
supernantant after absorption with 
Meningococcus 
cells 
Type II  tion 18 
(Scherp) 
l}ef eel 
100 
100 
100 
90 
Type I  poly- 
saccharide 
Prepara- 
tion 18 
per cent 
60-70 
90-100 
50~: 
?repara-  M6C or 
tion 18  Type I  'Scherp)  M9B2 
I__ 
mg./mL  rag/.ral,  per ten 
0.71  0.34  0 
0.04  0.015  0 
0.11  f 0.09  10 
0.03* 
0.002*  0.002"1 
0.061"  0.049* I  0 
t o.oo5"1 
90-100 
M6C or 
M9B2 
per ce~t 
40-50 
90-1~ 
50-100 
90-1~ 
* Determined  by micro method using Folin-Ciocalteau  reagent  (6, 7). 
:~ h  1/1600 dilution  of this  supernatant protected  against  100,000 lethal doses, as com- 
pared with a 1/3200 dilution of a control of serum with saline. 
removal of the protective antibody (Table II).  With a  Type II chicken anti- 
serum,  C135,  conversely,  the Type II suspension  removed more antibody N 
per milliliter of serum than did the Type I  suspension.  The very small amount 
of Type I  antipolysaccharide  found may have  been  due  to  traces  of group- 
specific antigen  in  the  polysaccharide  preparation.  It is  also  of interest  to 
note that after a second course of immunization, C85 showed a decrease in total 
antibody  N  with  almost  complete  disappearance  of  the  antipolysaccharide 
although  the  Type I  agglutinin  still  remained  considerably higher  than  the 
Type II agglutinin. 
In the case of 1-11095, more than twice as much antibody N  was taken out 
with  preparation  18  than  with  M6C  or  M9B2.  This  additional  amount  of 
antibody N  was not protective antibody since preparation  18 did not remove E.  A.  KABAT, C.  P.  MILLER, H.  KAISER, AND A.  Z.  FOSTER 
any more of the protective antibody than did the other two polysaccharides 
(Table II).  Some of  this  additional  antibody removed by Scherp polysac- 
charide, although not protective, was shown to be Type I specific by absorption 
experiments in which after removal of the antipolysaccharide from two samples 
of serum with M6C and with preparation 18, both supernatants still contained 
the  same  amount  of  Type  II agglutinin.  Subsequent  addition of  Type  I 
meningococcus suspension then showed the preparation 18 supernatant to con- 
TABLE  III 
Antibody Nitrogen and Mouse Protective  Power Removed  from Sera o/Patients Convalescing/tom 
Meningococcus Meningitis by Types I  and II Meningococci and by Purified  Type I 
Meningococcus Polysaccharide 
Percentage of protective power against 
Antibody N  removed per ml. of serum by  Type I meningococci in supernatant 
after absorption with 
~ase No.  Type  Meningococeus  Type I poly-  Meningococcus  Type I  po]y- 
cells  saccharide  cells  saccharide 
Type ] 
mg./m 
4  I  0.03 
8.2  ?  0.12 
9.1  I  0.04 
9.2  II  0.01 
(Acute phase) 
9.2  II  0.00 
10.1  I  0.06 
10.2  I  0.10 
11.1  ?  0.00 
11.2  I  0.01 
14.1  ?  0.00 
14.2  0.05 
A Normal  0.00 
B Normal  0.00 
Prepara-  M6C or 
Type I [  tion 18 
(Scherp)  M9B2 
rag./ml  rag/.ral,  mg/.ral. 
0.03  0.000  0.000 
0.07  0.027  0.004 
O. 04  O. 000  O. 000 
0.01  0.000  0.000 
0.01  0.000  0.000 
0.08  0.008  0.010 
0.10  0.007  0.005 
0.01  0.000  0.000 
0.05  0.010  0.015 
0.00  0.001  0.001 
0.00  0.003  0.003 
0.00 
0.00 
Type I  Type II 
per cent  per cent 
0  100 
10-20  100 
0  100 
0  100 
Prepara- 
tion 18 
(Scherp) 
#er cen~ 
100 
12-25 
50 
100 
M6C or 
M9B2 
>50 
50 
100 
100 
rain less antibody N  than did the M6C supernatant.  In this absorption ex- 
periment, the supernatants after removal of the antipolysaccharide with any of 
the  three preparations and of the Type II agglutinin with Type II suspension, 
still contained considerable amounts  of protective antibody which  was com- 
pletely removed with a  Type I  meningococcus suspension.  The horse anti- 
meningococcus antitoxin  was found  to  contain  only group-specific antibody 
since  both  Type I  and  II suspensions  removed equal amounts  of antibody 
nitrogen. 
The antibody response of a  number of humans recovering from meningo- 
coccus meningitis is given in Table III.  In practically all of these the amount 
of agglutinin N  found with Type II suspension was, within the limit of error, CttEMICAL  STUDIES  ON  BACTERIAL  AGGLUTINATION.  VII 
the same as with Type I  suspension indicating that the bulk of the antibody 
formed was group-specific.  Most of this antibody was probably not protective 
antibody, since with sera 10.1 and 10.2, removal of the antibody N with Type 
II suspension left all of the protective power in the supernatant.  Amounts of 
protective antibody too small to affect the value for Type I agglutinin N  were 
present, however, since absorption with Type I organisms removed most or all 
of the protective antibody from these sera without affecting the total agglutinin 
N.  Some of this protective antibody was antipolysaccharide which constituted 
but a small proportion of the total antibody N. 
Two sera (cases 8.2 and 14.2) showed a different type of antibody response, 
resembling more closely the rabbit and  chicken sera  in  Table II.  In  these 
sera more Type I  agglutinin was present than Type II agglutinin.  This dif- 
ference could not be accounted for by the antipolysaccharide present and pro- 
tective activity could only be removed from the serum by absorption with 
homologous Type I meningococcus suspension.  In the case of serum 8.2, more 
antibody N  was taken out of the serum with preparation 18 than with  M6C 
or M9B2, but this antibody did not appear to be associated with mouse protec- 
tion (of.  H1095-Table II).  With serum 14.2,  the removal of the antipolysac- 
charide also failed to lower the protective antibody in the supernatant. 
Several normal human sera were found to contain no measurable agglutinin 
to Type I  and Type II organisms, nor was any antipolysaccharide found in 
over 50 normal human sera. 
DISCUSSION 
The problem of outlining the antigenic composition of meningococci and de- 
termining the  chemical nature  of the substances which produce protective 
antibody on immunization has been  complicated by the fact that the principal 
antigens which stimulate antibody formation are group-specific and that these 
antibodies have little or no protective power.  Although both pneumococci 
and Type I meningococci possess type-specific  polysaccharides which induce 
the formation of protective antibody, in both horse and rabbit  antisera to 
the former group the antipoIysaccharide comprises by far the largest portion 
of the total antibody (4, 12), whereas in the latter group it genera]i  N consists 
of only a small fraction of the total antibody (II).  This  explains the failure to 
demonstrate any correlation between the total Type I agglutinin N in the sera 
and their protective potency (Table I). 
By correlating the total Type I and Type II agglutinin N, the antipolysac- 
charide content, and the relation of these antibodies to mouse  protection it has 
been  possible to demonstrate that rabbit and chicken Type I antimeningococcal 
sera contain type-specific antibodies capable of protecting  mice against in- 
oculation with virulent Type I  meningococci.  A portion, at least, of these 
antibodies are distinct from the antibody to the Type I  polysaccharide as 
determined with three different polysaccharide preparations (Table II). E.  A.  I(ABAT~  C.  P.  ~flLLER,  I-I.  KAISER,  AND  A.  Z.  ]~OSTER 
In a Type I horse antiserum, also, more protective antibody was found than 
could be removed by the Type I  polysaccharide, although in this serum the 
antipolysaccharide was found to be responsible for a considerably larger portion 
of the total protection.  This does not necessarily conflict with the findings of 
Rake  and  Scherp  (2)  that in several Type  I  antisera all of the protective 
activity was due to antipolysaccharide, since the antibody response of different 
horses may be expected to vary over  a wide range  and also since the Type I 
polysaccharide appears to be a much better antigen in the horse than in the 
rabbit, chicken, or in man (Tables II and III). 
In human meningococcal meningitis cases  treated with sulfonamides, the 
antibody formed is, in most instances, group-specific antibody as measured by 
the quantitative agglutinin methods.  Although some protective antibody is 
formed in these cases as well, the data indicate that the total weight of protec- 
tive antibody, including the Type I antipolysaccharide, is not large enough to 
be measurable by the quantitative agglutinin method.  This may in part ac- 
count for the failure of Thomas, Smith, and Dingle (15) to find any correlation 
between the degree of antibody response as  measured by the usual agglutina- 
tion tests and the severity or duration of illness.  In two cases  (8.2,  14.2), 
however, more Type I agglutinin N was found than could be accounted for by 
the sum of the Type II agglutinin and the Type I antipolysaccharide, and pro- 
tective activity was associated with this residual Type I  agglutinin, as was 
found to obtain with the animal anfisera.  The amounts of total agglutinin N 
and of anfipolysaccharide N  found in file serum of patients recovering from 
meningitis are of the same order as those found by Heidelberger and Anderson 
for anti-"C" and type-specific antipolysaccharide accompanying convalescence 
from pneumonia (7), indicating a similar wide individual variation in the human 
immune response to rapidly terminating infections. 
As yet, nothing is known about the chemical nature of the antigen responsible 
for the production of this new Type I specific protective antibody.  Although 
the evidence indicates that the Type I polysaccharide, even when prepared by 
methods which avoid the use of strong acid or alkali, does not react with anti- 
body to this antigen, it is quite possible that .the latter consists of polysac- 
charide bound  to  some  other  as  yet unidentified constituent in  the  intact 
meningococcus and that either autolysis of the  organism or the method of 
preparation liberates the polysaccharide.  However, it is equally possible that 
this other antigen is entirely unrelated to the Type I polysaccharide. 
In any event,  the present study provides a  very direct approach  to  the 
purification and isolation of this substance from the meningococcus, since by 
absorption both of the Type I  antipolysaccharide and of the group-specific 
agglutinin from the animal sera, antisera specific for this antigen could be ob- 
tained and used as a guide to chemical isolation.  Since this antigen is both 
Type I  specific and associated with the production of protective antibodies, 
the possibility that, if obtainable in pure form, it might provide an effective CHEMICAL STUDIES ON  BACTERIAL  AGGLUTINATION.  VII 
antigen for  active  immunization of humans against  Type  I  meningococcal 
meningitis should not be overlooked. 
SUMMARY 
1.  The quantitative method for the  estimation of agglutinins has been ap- 
plied to anfimeningococcal horse, rabbit, and chicken sera and to the sera of 
humans  convalescing  from  meningococcus  meningitis.  The  type-specific 
and group-specific agglutinin N can be measured, using homologous and hetero- 
logous suspensions of meningococci. 
2.  Type I horse, rabbit, and chicken antimeningococcal sera contain consid- 
erable amounts of antibody which cannot be removed either by Type II men- 
ingococcus suspension or by preparations of the Type I specific polysaccharide. 
This residual type-specific antibody has marked potency in protecting mice 
against subsequent infection with meningococci. 
3.  Most human convalescent sera contain group-specific antibody.  Small 
amounts of protective antibody and of antipolysaccharide are also formed. 
4.  Type I  antisera absorbed with Type I polysaccharide and with Type II 
meningococci could be used as a guide in the purification of this new antigen. 
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